Branched peptides as novel tumor-targeting agents for bladder cancer

Expert Review of Anticancer Therapy

Volumn 12, Issue 6, 2012, Pages 699-701

  Minervini, Andrea ^a   Siena, Giampaolo ^a   Falciani, Chiara ^b   Carini, Marco ^a   Bracci, Luisa ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

bladder cancer; branched peptides; diagnosis; intravesical chemotherapy; selective drug delivery; treatment

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; CHLORAMBUCIL; COMBRETASTATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; MONASTROL; NEUROTENSIN;

BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER RISK; CYSTECTOMY; CYSTOSCOPY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; EDITORIAL; ENCAPSULATION; HEALTH CARE COST; HUMAN; MOLECULARLY TARGETED THERAPY; RECURRENT CANCER; RISK ASSESSMENT; TRANSURETHRAL RESECTION; TREATMENT DURATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; HUMANS; NEUROTENSIN; PEPTIDES; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84862855655     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.57     Document Type: Editorial

References (18)

1. Colombel M, Soloway M, Akaza H et al. Epidemiology, staging, grading, and risk stratification of bladder cancer. Eur. Urol. (Suppl. 7), 618-626 (2008).
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
3. Venturini M, Ferretti S. [The Numbers of Cancer in Italy 2011]. Intermedia Editore, Brescia, Italy (2011).
4. Babjuk M, Oosterlinck W, Sylvester R et al. European Association of Urology (EAU) guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur. Urol. 59(6), 997-1008 (2011).
5. Hall MC, Chang SS, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J. Urol. 178, 2314-2330 (2007).
6. Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined ana lysis of 2596 patients from seven EORTC trials. Eur. Urol. 49(3), 466-477 (2006).
7. Kausch I, Sommerauer M, Montorsi F et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative ana lysis of prospective studies. Eur. Urol. 57(4), 595-606 (2010).
8. Kakiashvili DM, van Rhijn BW, Trottier G et al. Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment. BJU Int. 107(4), 540-546 (2011).
9. Falciani C, Pini A, Bracci L. Oligobranched peptides for tumor targeting: from magic bullets to magic forks. Expert Opin. Biol. Ther. 9(2), 171-178 (2009).
10. Tam JP. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc. Natl Acad. Sci. USA 85(15), 5409-5413 (1998).
11. Bracci L, Falciani C, Lelli B et al. Synthetic peptides in the form of dendrimers become resistant to protease activity. J. Biol. Chem. 278 (47), 46590-46595 (2003).
12. Bracci L, Lozzi L, Pini A et al. A branched peptide mimotope of the nicotinic receptor binding site is a potent synthetic antidote against the snake neurotoxin alpha-bungarotoxin. Biochemistry 41(32), 10194-10199 (2002).
13. Falciani C, Lozzi L, Pini A et al. Molecular basis of branched peptides resistance to enzyme proteolysis. Chem. Biol. Drug Des. 3, 216-221 (2007).
14. Falciani C, Fabbrini M, Pini A et al. Synthesis and biological activity of stable branched neurotensin peptides for tumor targeting. Mol. Cancer Ther. 9, 2441-2448 (2007).
15. Falciani C, Lelli B, Brunetti J et al. Modular branched neurotensin peptides for tumor target tracing and receptor-mediated therapy: a proof-of-concept. Curr. Cancer Drug Targets 10(7), 695-704 (2010).
16. Falciani C, Brunetti J, Pagliuca C et al. Design and in vitro evaluation of branched peptide conjugates: turning nonspecific cytotoxic drugs into tumor-selective agents. Chem. Med. Chem. 5, 567-574 (2010).
17. Falciani C, Accardo A, Brunetti J et al. Target-selective drug delivery through liposomes labeled with oligobranched neurotensin peptides. Chem. Med. Chem. 6(4), 678-685 (2011).
18. Minervini A, Siena G, Ravenni N et al. Branched peptides as a novel tumor-targeting agents for bladder cancer. Eur. Urol. 10(2), 606 (2011).